Oncology Corporate Profile
Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company's epigenetic drug discovery platform has yielded a proprietary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon's lead drug candidate, ricolinostat (ACY-1215), is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Acy-1215 + pomalidomide)||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||II||Celgene|
|Acy-1215||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||II||Celgene|
|Acy-1215 (+ bortezomib and dexamethasone)||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||I||Celgene|
|Acy-1215 (+ lenalidomide and dexamethasone)||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||I||Celgene|